IRIS Accounts Production v24.2.0.383 OC367519 designated member designated member 27.11.22 26.11.23 26.11.23 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhOC3675192022-11-26OC3675192023-11-26OC3675192022-11-272023-11-26OC3675192021-11-26OC3675192021-11-272022-11-26OC3675192022-11-26OC367519ns15:EnglandWales2022-11-272023-11-26OC367519ns14:PoundSterling2022-11-272023-11-26OC367519ns10:PartnerLLP12022-11-272023-11-26OC367519ns10:PartnerLLP22022-11-272023-11-26OC367519ns10:LimitedLiabilityPartnershipLLP2022-11-272023-11-26OC367519ns10:SmallEntities2022-11-272023-11-26OC367519ns10:AuditExempt-NoAccountantsReport2022-11-272023-11-26OC367519ns10:SmallCompaniesRegimeForAccounts2022-11-272023-11-26OC367519ns10:LimitedLiabilityPartnershipsSORP2022-11-272023-11-26OC367519ns10:FullAccounts2022-11-272023-11-26OC36751912022-11-272023-11-26OC367519ns10:PartnerLLP32022-11-272023-11-26OC367519ns10:RegisteredOffice2022-11-272023-11-26OC367519ns5:CurrentFinancialInstruments2023-11-26OC367519ns5:CurrentFinancialInstruments2022-11-26OC367519ns5:Non-currentFinancialInstruments2023-11-26OC367519ns5:Non-currentFinancialInstruments2022-11-26OC367519ns5:CapitalRedemptionReserve2023-11-26OC367519ns5:CapitalRedemptionReserve2022-11-26OC367519ns5:NetGoodwill2022-11-272023-11-26OC367519ns5:IntangibleAssetsOtherThanGoodwill2022-11-272023-11-26OC367519ns5:PlantMachinery2022-11-272023-11-26OC367519ns5:NetGoodwill2022-11-26OC367519ns5:NetGoodwill2023-11-26OC367519ns5:NetGoodwill2022-11-26OC367519ns5:PlantMachinery2022-11-26OC367519ns5:PlantMachinery2023-11-26OC367519ns5:PlantMachinery2022-11-26OC367519ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-11-26OC367519ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-11-26OC367519ns5:Non-currentFinancialInstrumentsns5:MoreThanFiveYears2023-11-26OC367519ns5:Non-currentFinancialInstrumentsns5:MoreThanFiveYears2022-11-26OC367519ns5:CapitalRedemptionReserve2022-11-26OC367519ns5:RevaluationReserve2023-11-26
REGISTERED NUMBER: OC367519 (England and Wales)















Unaudited Financial Statements for the Year Ended 26 November 2023

for

Fvz Pharma LLP

Fvz Pharma LLP (Registered number: OC367519)






Contents of the Financial Statements
for the Year Ended 26 November 2023




Page

General Information 1

Balance Sheet 2

Notes to the Financial Statements 5


Fvz Pharma LLP

General Information
for the Year Ended 26 November 2023







DESIGNATED MEMBERS: Z A Sharif
V Patel
M Fahim





REGISTERED OFFICE: Elthorne Gate
64 High Street
Pinner
HA5 5QA





REGISTERED NUMBER: OC367519 (England and Wales)






Fvz Pharma LLP (Registered number: OC367519)

Balance Sheet
26 November 2023

26.11.23 26.11.22
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 1,120,323 274,493
Tangible assets 5 24,582 24,772
1,144,905 299,265

CURRENT ASSETS
Stocks 100,725 20,625
Debtors 6 260,496 197,119
Cash at bank 42,959 19,688
404,180 237,432
CREDITORS
Amounts falling due within one year 7 615,371 131,130
NET CURRENT (LIABILITIES)/ASSETS (211,191 ) 106,302
TOTAL ASSETS LESS CURRENT
LIABILITIES

933,714

405,567

CREDITORS
Amounts falling due after more than
one year

8

716,235

339,348
NET ASSETS ATTRIBUTABLE TO
MEMBERS

217,479

66,219

Fvz Pharma LLP (Registered number: OC367519)

Balance Sheet - continued
26 November 2023

26.11.23 26.11.22
Notes £    £    £    £   
LOANS AND OTHER DEBTS DUE
TO MEMBERS

9

217,477

66,217

MEMBERS' OTHER INTERESTS
Other reserves 10 2 2
217,479 66,219

TOTAL MEMBERS' INTERESTS
Loans and other debts due to
members

9

217,477

66,217
Members' other interests 2 2
Amounts due from members 6 - (88,859 )
217,479 (22,640 )

The LLP is entitled to exemption from audit under Section 477 of the Companies Act 2006 as applied to LLPs by the Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008 for the year ended 26 November 2023.

The members acknowledge their responsibilities for:
(a)ensuring that the LLP keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 as applied to LLPs by the Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the LLP as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 as applied to LLPs by the Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008 relating to financial statements, so far as applicable to the LLP.

Fvz Pharma LLP (Registered number: OC367519)

Balance Sheet - continued
26 November 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to LLPs subject to the small LLPs regime.

In accordance with Section 444 of the Companies Act 2006 as applied to LLPs by the Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008, the Income Statement has not been delivered.

The financial statements were approved by the members of the LLP and authorised for issue on 9 July 2024 and were signed by:




V Patel - Designated member




M Fahim - Designated member


Fvz Pharma LLP (Registered number: OC367519)

Notes to the Financial Statements
for the Year Ended 26 November 2023

1. STATUTORY INFORMATION

Fvz Pharma LLP is registered in England and Wales. The LLP's registered number and registered office address can be found on the General Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial reporting Standard applicable in the UK and Republic of Ireland" and the companies Act 2006.
The financial statements have been prepared under historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2023, is being amortised evenly over its estimated useful life of ten years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance and 15% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

3. EMPLOYEE INFORMATION

The average number of employees during the year was 8 (2022 - 4 ) .

Fvz Pharma LLP (Registered number: OC367519)

Notes to the Financial Statements - continued
for the Year Ended 26 November 2023

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 27 November 2022 286,427
Additions 901,335
At 26 November 2023 1,187,762
AMORTISATION
At 27 November 2022 11,934
Charge for year 55,505
At 26 November 2023 67,439
NET BOOK VALUE
At 26 November 2023 1,120,323
At 26 November 2022 274,493

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 27 November 2022 26,550
Additions 3,836
At 26 November 2023 30,386
DEPRECIATION
At 27 November 2022 1,778
Charge for year 4,026
At 26 November 2023 5,804
NET BOOK VALUE
At 26 November 2023 24,582
At 26 November 2022 24,772

Fvz Pharma LLP (Registered number: OC367519)

Notes to the Financial Statements - continued
for the Year Ended 26 November 2023

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
26.11.23 26.11.22
£    £   
Trade debtors 195,499 79,153
Amounts due from members - 88,859
Other debtors 28,075 15,897
VAT 32,973 10,026
Prepayments and accrued income 3,949 3,184
260,496 197,119

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
26.11.23 26.11.22
£    £   
Bank loans and overdrafts 4,196 39,083
Loans 84,554 -
Trade creditors 198,334 53,971
Social security and other taxes 1,666 239
Other creditors 308,760 34,739
Wages Payable 17,861 3,098
615,371 131,130

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN
ONE YEAR
26.11.23 26.11.22
£    £   
Bank loans more 5 yr by instal 716,235 184,367
Other creditors - 154,981
716,235 339,348

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 716,235 184,367

Fvz Pharma LLP (Registered number: OC367519)

Notes to the Financial Statements - continued
for the Year Ended 26 November 2023

9. LOANS AND OTHER DEBTS DUE TO MEMBERS
26.11.23 26.11.22
£    £   
Loans from members 66,217 66,217
Amounts owed to members in respect of profits 151,260 -
217,477 66,217

Falling due within one year 217,477 66,217

Loans and other debts due to members are unsecured and would rank parsi passu with other unsecured creditors in the event of a winding up.

10. RESERVES
Other
reserves
£   
At 27 November 2022 2
At 26 November 2023 2